2Indexed trials
drug · Product Intelligence
Exemestane
Pipeline Intelligence
Exemestane: 2 indexed trials, 2 sponsors; 0 linked Orange Book patents and 12 FDA-linked events where matched.
2Sponsors
0Orange Book patent links
12FDA-linked events
Development evidence
NCT02069093Novartis Pharmaceuticals · out_of_scopePHASE2
NCT02894398iOMEDICO AG · out_of_scopePHASE2
FDA / patent evidence
Orange Book match found; no listed patent relation was retained for this product match.
Regulatory context
FDA_APPROVALEXEMESTANE · 2022-05-20
FDA_APPROVALEXEMESTANE · 2020-04-13
FDA_APPROVALEXEMESTANE · 2019-08-08
FDA_APPROVALEXEMESTANE · 2019-02-21
FDA_APPROVALEXEMESTANE · 2018-12-28
FDA_APPROVALEXEMESTANE · 2018-10-03
FDA_APPROVALEXEMESTANE · 2018-04-27
FDA_APPROVALEXEMESTANE · 2017-07-26
FDA_APPROVALEXEMESTANE · 2017-03-10
FDA_APPROVALEXEMESTANE · 2014-07-28
FDA_APPROVALEXEMESTANE · 2011-04-01
FDA_APPROVALAROMASIN · 1999-10-21
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.